

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9989)

**POLL RESULTS OF THE 2020 THIRD EXTRAORDINARY
GENERAL MEETING HELD ON AUGUST 31, 2020**

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that, at the 2020 third extraordinary general meeting of the Company (the “**EGM**”) held at 2:30 p.m. on Monday, August 31, 2020 at Ballroom, 2/F, L’Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC, all the proposed resolutions set out in the notice of the EGM were passed by way of poll. For details of the resolutions considered at the EGM, the Shareholders may refer to the notice of the EGM dated August 10, 2020 and the circular of the EGM dated August 10, 2020 of the Company (the “**Circular**”). Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, the total number of Share in issue is 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). No Shareholder was required to abstain from voting on the resolutions under the Listing Rules. There was no Share entitling the holder to attend the meeting and abstain from voting in favour of the resolutions under Rule 13.40 of the Listing Rules. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM. Tricor Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking in respect of the H Shares at the EGM. The convening of the EGM was in compliance with the Company Law of the PRC and the Articles of Association.

I. CONVENING OF THE MEETING

The total number of Shares entitling the holders to attend and vote on the resolutions at the EGM was 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). The total number of Shares with voting rights represented by the Shareholders attending the EGM in person or by proxy was 1,005,209,346 Shares (including 973,845,546 A Shares and 31,363,800 H Shares), representing approximately 68.5076% of the total number of Shares.

II. POLL RESULTS OF THE EGM

The poll results in respect of the respective resolutions at the EGM are set out below:

NO.	ORDINARY RESOLUTIONS EFFECTED BY CUMULATIVE VOTING SYSTEM	NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.00	To elect non-independent Directors of the fifth session of the Board:	/		
1.01	Re-elect Mr. Li Li as an non-independent Director of the Company;	1,001,759,069 (99.6568%)		
1.02	Re-elect Mr. Sun Xuan as an non-independent Director of the Company;	1,002,310,969 (99.7117%)		
1.03	Re-elect Ms. Li Tan as an non-independent Director of the Company;	1,002,310,969 (99.7117%)		
1.04	Re-elect Mr. Shan Yu as an non-independent Director of the Company;	1,002,310,969 (99.7117%)		
1.05	Re-elect Mr. Bu Haihua as an non-independent Director of the Company.	1,002,310,969 (99.7117%)		
2.00	To elect independent non-executive Directors of the fifth session of the Board:	/		
2.01	Re-elect Mr. Chen Junfa as an independent non-executive Director of the Company;	1,002,317,469 (99.7123%)		
2.02	Re-elect Mr. Wang Zhaohui as an independent non-executive Director of the Company;	1,002,346,646 (99.7152%)		
2.03	Re-elect Dr. Lu Chuan as an independent non-executive Director of the Company.	1,002,346,646 (99.7152%)		
3.00	To elect Supervisors of the fifth session of the Supervisory Committee:	/		
3.01	Re-elect Mr. Zheng Zehui as a Supervisor of the Company;	1,002,251,069 (99.7057%)		
3.02	Re-elect Ms. Tang Haijun as a Supervisor of the Company.	1,002,208,469 (99.7015%)		

RESOLUTIONS OF NON-CUMULATIVE VOTING				
NO.	ORDINARY RESOLUTION	NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
4.00	To consider and approve the remuneration of the independent non-executive Directors of the fifth session of the Board.	1,002,346,646 (99.7152%)	2,862,700 (0.2848%)	0 (0.0000%)
NO.	SPECIAL RESOLUTIONS	NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
5.00	To consider and approve the proposal for the Company and its wholly-owned subsidiary to apply for credit lines and provide guarantees to the banks.	1,002,336,646 (99.7142%)	2,872,700 (0.2858%)	0 (0.0000%)
6.00	To consider and approve the amendments to the articles of association of the Company.	1,002,347,146 (99.7153%)	2,862,200 (0.2847%)	0 (0.0000%)

Note: Under the cumulative voting system, “Against” and “Abstain” votes will be considered invalid.

As more than half of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the resolutions numbered 1 to 4, these resolutions were duly passed as ordinary resolutions.

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the resolutions numbered 5 to 6, these resolutions were duly passed as special resolutions.

III. APPOINTMENT OF DIRECTORS AND SUPERVISORS

At the EGM, Mr. Li Li, Ms. Li Tan, Mr. Shan Yu, Mr. Sun Xuan and Mr. Bu Haihua were re-elected as non-independent Directors of the fifth session of the Board; and Mr. Chen Junfa, Mr. Wang Zhaohui and Dr. Lu Chuan were re-elected as independent non-executive Directors of the fifth session of the Board for a term of three years commencing from the date of the EGM. Mr. Zheng Zehui and Ms. Tang Haijun were elected as Supervisors of the fifth session of the Supervisory Committee for a term of three years commencing from the date of the EGM.

For the biographies of the Directors of the fifth session of the Board and the Supervisors for the fifth session of the Supervisory Committee, please refer to the Circular. As of the date of this announcement, there is no change in the biographies of the Directors and Supervisors.

IV.ELECTION OF CHAIRMAN OF THE BOARD, VICE CHAIRMAN OF THE BOARD, COMPOSITION OF THE BOARD, CHAIRMAN OF THE SUPERVISORY COMMITTEE AND EMPLOYEE REPRESENTATIVE SUPERVISOR

The Board is pleased to announce that immediately following the EGM, Mr. Li Li and Mr. Sun Xuan were unanimously elected by the Board as the chairman and the vice chairman of the fifth session of the Board, respectively. Their terms of office would be consistent with the terms of office of the fifth session of the Board.

Also, Mr. Li Li, Ms. Li Tan, Mr. Shan Yu, and Mr. Sun Xuan were unanimously elected by the Board as the executive Directors, Mr. Bu Haihua was unanimously elected by the Board as the non-executive Director and Mr. Chen Junfa, Mr. Wang Zhaohui and Dr. Lu Chuan were unanimously elected by the Board as the independent non-executive Directors.

Also, immediately following the EGM, Mr. Zheng Zehui was unanimously elected by the Supervisory Committee as the chairman of the fifth session of the Supervisory Committee. His term of office would be consistent with his term of office as a Supervisor.

The fifth session of the Supervisory Committee comprises three Supervisors, including Mr. Zheng Zehui, Ms. Tang Haijun and one employee representative Supervisor, namely Ms. Su Jilan (“**Ms. Su**”). At the employees’ representative meeting convened by the Company on August 31, 2020, Ms. Su was re-elected as the employee representative Supervisor. Her term of office was consistent with the term of other Supervisors.

The biographical details of Ms. Su are set out as follows:

Ms. Su Jilan (蘇紀蘭), aged 40, is an employee Supervisor and the deputy manager of the quality inspection department of the Company. Ms. Su joined the Company in February 2004 and was appointed as our employee Supervisor in December 2007.

Ms. Su graduated from Xi’an Jiaotong University in China with a bachelor of science degree in pharmacy in July 2001. Ms. Su obtained the qualification of assistant engineer from the Department of Human Resources of Shaanxi Province in August 2002.

Ms. Su will enter into a service contract with the Company. The term of her appointment will be from the expiration of the term of the fourth session of the Supervisory Committee to the end of the term of the fifth session of the Supervisory Committee. According to the Articles of Association, Ms. Su may seek re-election after the expiration of the term of her appointment. Ms. Su will not be entitled to any remuneration from the Company in respect of her service as Supervisor.

Save as disclosed above, Ms. Su did not hold any other positions of the Company or its subsidiaries, nor did she hold any directorships in any other public companies within the three years prior to the date of her appointments, of which the securities are listed on any securities market in Hong Kong or overseas and nor did she have other major appointments and professional qualifications.

To the best knowledge of the Company, Ms. Su does not have any relationship with any other Directors, senior management, substantial Shareholders or Controlling Shareholders, and does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance and has not been subject to any disciplinary action by the CSRC or any other relevant authorities or the Hong Kong Stock Exchange.

Save as disclosed above, there is no other information required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, nor are there any other matters that need to be brought to the attention of the Shareholders, relating to the appointment of Ms. Su.

V. APPOINTMENT OF CHAIRMEN AND MEMBERS OF BOARD COMMITTEES

Immediately following the EGM, the Board appointed the following chairmen and members of the Strategy Committee, Audit Committee, Remuneration and Evaluation Committee and Nomination Committee under the fifth session of the Board with the same terms of office of the fifth session of the Board:

Strategy Committee

The Strategy Committee consists of three members, namely Mr. Li Li, Ms. Li Tan and Dr. Lu Chuan. Mr. Li Li has been appointed as the chairman of the Strategy Committee.

Audit Committee

The Audit Committee consists of three members, namely Mr. Chen Junfa, Dr. Lu Chuan and Mr. Wang Zhaohui. Mr. Chen Junfa has been appointed as the chairman of the Audit Committee.

Remuneration and Evaluation Committee

The Remuneration and Evaluation Committee consists of three members, namely Mr. Wang Zhaohui, Mr. Chen Junfa and Mr. Li Li. Mr. Wang Zhaohui has been appointed as the chairman of the Remuneration and Evaluation Committee.

Nomination Committee

The Nomination Committee consists of three members, namely Dr. Lu Chuan, Mr. Li Li and Mr. Chen Junfa. Dr. Lu Chuan has been appointed as the chairman of the Nomination Committee.

VI. RE-APPOINTMENT OF THE GENERAL MANAGER OF THE COMPANY

The Board is pleased to announce that immediately following the EGM, Mr. Shan Yu was unanimously re-elected by the Board as the general manager of the Company. His term of office would be consistent with the term of office of the fifth session of the Board.

For the biography of Mr. Shan Yu, please refer to the Circular. As of the date of this announcement, the biography of Mr. Shan Yu has not changed.

VII. AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board is pleased to announce that the proposed amendments to the Articles of Association were duly approved by the Shareholders at the EGM. The proposed amendments to the Articles of Association have taken effect since August 31, 2020.

By Order of the Board of Directors
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
August 31, 2020

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xuan; the non-executive director of the Company is Mr. Bu Haihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.